All Stories

  1. Active Surveillance in RET Gene Carriers Belonging to Families with Multiple Endocrine Neoplasia

    Article • Cancers, November 2021, MDPI AG

    Dr David Viola

  2. Osteonecrosis of the jaw: a rare but possible side effect in thyroid cancer patients treated with tyrosine-kinase inhibitors and bisphosphonates

    Article • Journal of Endocrinological Investigation, July 2021, Springer Science + Business Media

    Dr David Viola

  3. BRAF V600E Status Sharply Differentiates Lymph Node Metastasis-associated Mortality Risk in Papillary Thyroid Cancer

    Article • The Journal of Clinical Endocrinology & Metabolism, July 2021, Endocrine Society

    Dr David Viola

  4. Ca19.9 Positivity and Doubling Time Are Prognostic Factors of Mortality in Patients with Advanced Medullary Thyroid Cancer with No Evidence of Structural Disease Progression According to Response Evaluation Criteria in Solid Tumors

    Article • Thyroid, July 2021, Mary Ann Liebert Inc

    Dr David Viola

  5. Tall cell percentage alone in PTC without aggressive features should not guide patients’ clinical management

    Article • The Journal of Clinical Endocrinology & Metabolism, June 2021, Endocrine Society

    Dr David Viola

  6. Thyroid Cancers: From Surgery to Current and Future Systemic Therapies through Their Molecular Identities

    Article • International Journal of Molecular Sciences, March 2021, MDPI AG

    Dr David Viola

  7. Prevalence and Risk Factors of Developing Fistula or Organ Perforation in Patients Treated with Lenvatinib for Radioiodine-Refractory Thyroid Cancer

    Article • European Thyroid Journal, January 2021, Karger Publishers

    Dr David Viola

  8. No difference in the outcome of metastatic thyroid cancer patients when using recombinant or endogenous TSH

    Article • European Journal of Endocrinology, October 2020, Bioscientifica

    Dr David Viola

  9. Role of Prophylactic Central Compartment Lymph Node Dissection on the Outcome Of Patients With Papillary Thyroid Carcinoma and Synchronous Ipsilateral Cervical Lymph Node Metastases

    Article • Endocrine Practice, August 2020, Elsevier

    Dr David Viola

  10. Thyroglobulin Changes are Highly Dependent on TSH in Low-risk DTC Patients not Treated with Radioiodine

    Article • The Journal of Clinical Endocrinology & Metabolism, May 2020, Endocrine Society

    Dr David Viola

  11. Proteinuria is a late-onset adverse event in patients treated with cabozantinib

    Article • Journal of Endocrinological Investigation, May 2020, Springer Science + Business Media

    Dr David Viola

  12. Outcome of classical (CVPTC) and follicular (FVPTC) variants of papillary thyroid cancer: 15 years of follow-up

    Article • Endocrine, March 2020, Springer Science + Business Media

    Dr David Viola

  13. Medullary thyroid cancer treated with vandetanib: predictors of a longer and durable response

    Article • Endocrine Related Cancer, February 2020, Bioscientifica

    Prof. Paolo Piaggi, Dr David Viola

  14. BRAF V600E status may facilitate decision-making on active surveillance of low-risk papillary thyroid microcarcinoma

    Article • European Journal of Cancer, January 2020, Elsevier

    Dr David Viola

  15. DELAYED 131-I FIRST TREATMENT AFTER SURGERY HAS NO IMPACT ON THE MEDIAN TERM OUTCOME OF PATIENTS WITH INTERMEDIATE RISK DIFFERENTIATED THYROID CANCER

    Article • Endocrine Practice, January 2020, AACE Corp (American Association of Clinical Endocrinologists)

    Prof. Paolo Piaggi, Dr David Viola

  16. Active Surveillance in Papillary Thyroid Microcarcinomas is Feasible and Safe: Experience at a Single Italian Center

    Article • The Journal of Clinical Endocrinology & Metabolism, October 2019, Endocrine Society

    Prof. Paolo Piaggi, Dr David Viola

  17. Genetic Landscape of Somatic Mutations in a Large Cohort of Sporadic Medullary Thyroid Carcinomas Studied by Next-Generation Targeted Sequencing

    Article • iScience, October 2019, Elsevier

    Dr David Viola

  18. Lenvatinib Administered via Nasogastric Tube in Poorly Differentiated Thyroid Cancer

    Article • Case Reports in Endocrinology, September 2019, Hindawi Publishing Corporation

    Dr David Viola

  19. Twenty-Five Years Experience on RET Genetic Screening on Hereditary MTC: An Update on The Prevalence of Germline RET Mutations

    Article • Genes, September 2019, MDPI AG

    Dr David Viola

  20. Risk of incident circulatory disease in patients treated for differentiated thyroid carcinoma with no history of cardiovascular disease

    Article • Clinical Endocrinology, April 2019, Wiley

    Dr David Viola

  21. Management of Medullary Thyroid Cancer

    Article • Endocrinology and Metabolism Clinics of North America, March 2019, Elsevier

    Dr David Viola

  22. Fifty years after the first description, the MEN 2B syndrome diagnosis is still late: description of two recent cases

    Article • The Journal of Clinical Endocrinology & Metabolism, December 2018, Endocrine Society

    Dr David Viola

  23. Less than 2% of the Low- and Intermediate-Risk Differentiated Thyroid Cancers Show Distant Metastases at Post-Ablation Whole-Body Scan

    Article • European Thyroid Journal, December 2018, Karger Publishers

    Dr David Viola

  24. Lung Recurrence of Papillary Thyroid Cancer Diagnosed With Antithyroglobulin Antibodies After 10 Years From Initial Treatment

    Article • Frontiers in Endocrinology, October 2018, Frontiers

    Dr David Viola

  25. BRAF V600E Confers Male Sex Disease-Specific Mortality Risk in Patients With Papillary Thyroid Cancer

    Article • Journal of Clinical Oncology, September 2018, American Society of Clinical Oncology (ASCO)

    Dr David Viola

  26. Clinical, pathological and genetic features of anaplastic and poorly differentiated thyroid cancer: A single institute experience

    Article • Oncology Letters, April 2018, Spandidos Publications

    Dr David Viola, Prof. Paolo Piaggi

  27. Patient Age–Associated Mortality Risk Is Differentiated by BRAF V600E Status in Papillary Thyroid Cancer

    Article • Journal of Clinical Oncology, February 2018, American Society of Clinical Oncology (ASCO)

    Dr David Viola

  28. BRAF V600E Mutation-Assisted Risk Stratification of Solitary Intrathyroidal Papillary Thyroid Cancer for Precision Treatment

    Article • JNCI Journal of the National Cancer Institute, November 2017, Oxford University Press (OUP)

    Dr David Viola

  29. Real-life management and outcome of thyroid carcinoma-related bone metastases: results from a nationwide multicenter experience

    Article • Endocrine, November 2017, Springer Science + Business Media

    Dr David Viola

  30. KIF5B/RET Rearrangement in a Carcinoma of the Thyroid Gland: A Case Report of a Fatal Disease

    Article • The Journal of Clinical Endocrinology & Metabolism, July 2017, Endocrine Society

    Dr David Viola

  31. The Prognostic Value of Tumor Multifocality in Clinical Outcomes of Papillary Thyroid Cancer

    Article • The Journal of Clinical Endocrinology & Metabolism, June 2017, Endocrine Society

    Professor Alfred King Lam, Dr David Viola

  32. Protein kinase inhibitors for the treatment of advanced and progressive radiorefractory thyroid tumors: From the clinical trials to the real life

    Article • Best Practice & Research Clinical Endocrinology & Metabolism, June 2017, Elsevier

    Dr David Viola

  33. Targeted Therapy in Thyroid Cancer: State of the Art

    Article • Clinical Oncology, May 2017, Elsevier

    Dr David Viola

  34. Postoperative thyroglobulin and neck ultrasound in the risk re-stratification and decision to perform 131I ablation

    Article • The Journal of Clinical Endocrinology & Metabolism, December 2016, Endocrine Society

    MD Carlotta CG Giani, Dr David Viola, Prof. Paolo Piaggi

  35. Papillary thyroid microcarcinoma and active surveillance

    Article • The Lancet Diabetes & Endocrinology, December 2016, Elsevier

    Dr David Viola

  36. Papillary Thyroid Carcinoma With Rare Exon 15 BRAF Mutation Has Indolent Behavior: A Single-Institution Experience

    Article • The Journal of Clinical Endocrinology & Metabolism, November 2016, Endocrine Society

    Dr David Viola, Prof. Paolo Piaggi

  37. Role of YAP-1 in Thyroid Tumor Progression and Outcome

    Article • Applied Immunohistochemistry & Molecular Morphology, October 2016, Wolters Kluwer Health

    Dr David Viola

  38. Thyroid Cancer: Is Really Less More?

    Article • Endocrinology & Metabolism International Journal, August 2016, MedCrave Group LLC

    Dr David Viola

  39. Correction to Lancet Diabetes Endocrinol 2016; published online May 27. http://dx.doi.org/10.1016/S2213-8587(16)30041-9

    Article • The Lancet Diabetes & Endocrinology, August 2016, Elsevier

    Dr David Viola

  40. New insights in the molecular signature of advanced medullary thyroid cancer: evidence of a bad outcome of cases with double RET mutations

    Article • Journal of Medical Genetics, July 2016, BMJ

    Dr David Viola, Prof. Paolo Piaggi

  41. Treatment of advanced thyroid cancer with targeted therapies: ten years of experience

    Article • Endocrine Related Cancer, April 2016, Bioscientifica

    Dr David Viola

  42. Differential Clinicopathological Risk and Prognosis of Major Papillary Thyroid Cancer Variants

    Article • The Journal of Clinical Endocrinology & Metabolism, January 2016, Endocrine Society

    Dr David Viola

  43. Cabozantinib: an orphan drug for thyroid cancer

    Article • Expert Opinion on Orphan Drugs, November 2015, Informa Healthcare

    Dr David Viola

  44. Prophylactic Central Compartment Lymph Node Dissection in Papillary Thyroid Carcinoma: Clinical Implications Derived From the First Prospective Randomized Controlled Single Institution Study

    Article • The Journal of Clinical Endocrinology & Metabolism, April 2015, Endocrine Society

    Dr David Viola, Prof. Paolo Piaggi

  45. Association Between BRAF V600E Mutation and Recurrence of Papillary Thyroid Cancer

    Article • Journal of Clinical Oncology, January 2015, American Society of Clinical Oncology (ASCO)

    Dr David Viola, Professor Alfred King Lam

  46. Twenty years of lesson learning: how does theRETgenetic screening test impact the clinical management of medullary thyroid cancer?

    Article • Clinical Endocrinology, December 2014, Wiley

    Dr David Viola

  47. How to Manage Patients with Differentiated Thyroid Cancer and a Rising Serum Thyroglobulin Level

    Article • Endocrinology and Metabolism Clinics of North America, June 2014, Elsevier

    Dr David Viola

  48. FoxP3 Expression in Papillary Thyroid Carcinoma: A Possible Resistance Biomarker to Iodine 131 Treatment

    Article • Thyroid, February 2014, Mary Ann Liebert Inc

    Dr David Viola

  49. Medullary thyroid cancer in children

    Article • January 2014, Karger Publishers

    Dr David Viola

  50. Cabozantinib (XL184) for the treatment of locally advanced or metastatic progressive medullary thyroid cancer

    Article • Future Oncology, August 2013, Future Medicine

    Dr David Viola

  51. Patients With Differentiated Thyroid Cancer Who Underwent Radioiodine Thyroid Remnant Ablation With Low-Activity131I After Either Recombinant Human TSH or Thyroid Hormone Therapy Withdrawal Showed the Same Outcome After a 10-Year Follow-up

    Article • The Journal of Clinical Endocrinology & Metabolism, July 2013, Endocrine Society

    Dr David Viola, Prof. Paolo Piaggi

  52. Association Between BRAF V600E Mutation and Mortality in Patients With Papillary Thyroid Cancer

    Article • JAMA, April 2013, American Medical Association (AMA)

    Dr David Viola, Professor Alfred King Lam

  53. TheBRAFV600EMutation Is an Independent, Poor Prognostic Factor for the Outcome of Patients with Low-Risk Intrathyroid Papillary Thyroid Carcinoma: Single-Institution Results from a Large Cohort Study

    Article • The Journal of Clinical Endocrinology & Metabolism, December 2012, Endocrine Society

    Dr David Viola, Prof. Paolo Piaggi

  54. Modifications in the Papillary Thyroid Cancer Gene Profile Over the Last 15 Years

    Article • The Journal of Clinical Endocrinology & Metabolism, September 2012, Endocrine Society

    Dr David Viola

  55. An idic(15) associated with POF (premature ovarian failure): Molecular cytogenetic definition of a case and review of the literature

    Article • Gene, July 2012, Elsevier

    Dr David Viola, dr Angelo Valetto

  56. Incidental versus clinically evident thyroid cancer: A 5-year follow-up study

    Article • Head & Neck, February 2012, Wiley

    Dr David Viola

  57. In silico and in vitro analysis of rare germline allelic variants of RET oncogene associated with medullary thyroid cancer

    Article • Endocrine Related Cancer, August 2011, Bioscientifica

    Dr David Viola, Prof. Paolo Piaggi

  58. RET genetic screening of sporadic medullary thyroid cancer (MTC) allows the preclinical diagnosis of unsuspected gene carriers and the identification of a relevant percentage of hidden familial MTC (FMTC)

    Article • Clinical Endocrinology, January 2011, Wiley

    Dr David Viola

  59. Surgical Treatment of Low- and Intermediate-Risk Papillary Thyroid Cancer with Minimally Invasive Video-Assisted Thyroidectomy

    Article • The Journal of Clinical Endocrinology & Metabolism, May 2009, Endocrine Society

    Dr David Viola

  60. BRAFV600EMutation and Outcome of Patients with Papillary Thyroid Carcinoma: A 15-Year Median Follow-Up Study

    Article • The Journal of Clinical Endocrinology & Metabolism, October 2008, Endocrine Society

    Dr David Viola